论文部分内容阅读
研究中所采用的小细胞肺癌单抗(2F_7),是由上海市肿瘤所研制,经Protein A-Sepharose CL4B柱纯化制得。以Iodogen法使每mg2F_7约标上60MBq的~(131)I,用放免法进行标记单抗与靶细胞结合的活性检测,最后经无菌等处理得到~(131)I-2F_7的静脉滴注液。病员经痰脱落细胞病理确诊为小细胞肺癌,胸片为中央型肿块,共5例男性,1例女性,其中4例经一个疗程的药物治疗。病员预先经甲状腺封闭,用适量抗过敏药物及单抗皮肤试验等处理,一次滴注1～1.2mg的~(131)I-2F_7,于48～120小时内多
The small cell lung cancer monoclonal antibody (2F_7) used in the study was developed by the Shanghai Cancer Institute and purified on a Protein A-Sepharose CL4B column. The Iodogen method was used to label approximately 60 MBq of 131I per mg of 2F_7. The binding activity of the labeled monoclonal antibody to target cells was determined by radioimmunoassay. Finally, the intravenous infusion of ~(131)I-2F_7 was obtained by aseptic treatment. liquid. The patients were diagnosed as small cell lung cancer by patellar exfoliative cytopathology. The chest radiograph was a central mass. There were 5 males and 1 female, 4 of whom were treated with a course of medication. The patient was pre-transplanted with thyroid gland and treated with appropriate anti-allergic drugs and mono-inhibitory skin tests. One infusion of 1 to 1.2 mg of 131 I-2F_7 took place within 48 to 120 hours.